Will targeted therapy hold its promise? An evidence-based review

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 104-111

  Murdoch, David ^a   Sager, Jason ^b,c  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 36549055697     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f44b12     Document Type: Review

References (42)

1. Geffen DB, Man S. New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J 2002; 4:1124-1131.
2. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007; 62:53-61.
3. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122:598-609.
4. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:7565-7573.
5. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal carcinoma. J Clin Oncol 2006; 24:5601-5608.
6. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664.
7. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109:1804-1810.
8. Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005; 8:298-310.
9. Gasparini G, Longo R, Torino F, et al. Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 2006; 57:79-101.
10. Coppin C, Porzsolt F, Autenrieth M, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2004, Issue 3. Art. no.: CD001425.
11. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714.
12. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706-3712.
13. Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109:2077-2082.
14. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
15. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-4423.
16. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-3127.
17. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984-1992.
18. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
19. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22:2654-2661.
20. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
21. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
23. Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107:2254-2261.
24. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1:847-855.
25. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI - 774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
26. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11:6414-6421.
27. Ross HJ, Hart LL, Swanson PM, et al. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 2006; 54:69-77.
28. Chong G, Bhatnagar A, Cunningham D, et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 2006; 17:437-442.
29. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-3705.
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
31. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45:269-276.
32. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
33. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
34. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004; 10 (1 Pt 1):68-75.
35. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-843.
36. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2006; 24:3831-3837.
37. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25 (18S): abstract LBA1.
38. Press release (17 Apr 2007). Merck KGaA: Largest ever Erbitux trial shows significant increase in progression-free survival in metastatic colorectal cancer patients [online]. Available from URL: http://news.merck.de [Accessed 2007 Oct 5].
39. Press release (2 Apr 2007). Amgen discontinues Vectibix™ treatment in PACCE trial evaluating Vectibix™ as part of triple combination regimen [online]. Available from URL: http://www.medicalnewstoday.com/articles/ 66752.php [Accessed 2007 Sep 10].
40. Press release (17 Mar 2006). TeGenero Mab causes shock side-effects in UK trial [online]. Available from URL: http://www.pharmaceutical-business-review. com [Accessed 2007 Sep 10].
41. Anonymous. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (followed by surgery for selected patients) for Stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007; 5: 79-81.
42. Press release (12 Sep 2007). Global phase III trial to evaluate sunitinib malate combined with erlotinib [online]. Available from URL: http://www.worldpharmanews.com [Accessed 2007 Oct 5].